• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      MDRNA gets FDA approval for Osteoporosis Nasal Spray

      Posted AtBizjournals.com

      MDRNA Inc. said the U.S. Food and Drug Administration (FDA) has approved its application for a nasal spray for treating osteoporosis and that the product will be sold by the Bothell biotech’s partner, Par Pharmaceutical Companies Inc.

      Shares in MDRNA (NASDAQ: MRNA) soared in Tuesday trading, rising more than 75 percent, rising $1.16 to close at $2.70.

      MDRNA originally developed the calcitonin-salmon nasal spray when the company was known as Nastech Pharmaceutical Co. in the early 2000s and the company signed a deal with Par five years ago to market and sell the product.

      “Revenue generated from the sale of calcitonin-salmon by Par will provide us with working capital to help advance our RNAi programs,” said J. Michael French, president and CEO of MDRNA, in a statement.

      June 10, 2009


      Share this Article!

    Back to top^